> Details

Lee, Bang‐Ning; Gao, Hui; Cohen, Evan N.; Badoux, Xavier; Wierda, William G.; Estrov, Zeev; Faderl, Stefan H.; Keating, Michael J.; Ferrajoli, Alessandra; Reuben, James M.

Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia
  • Contributor: Lee, Bang‐Ning; Gao, Hui; Cohen, Evan N.; Badoux, Xavier; Wierda, William G.; Estrov, Zeev; Faderl, Stefan H.; Keating, Michael J.; Ferrajoli, Alessandra; Reuben, James M.
  • Published: Wiley, 2011
  • Published in: Cancer, 117 (2011) 17, Seite 3999-4008
  • Language: English
  • DOI: 10.1002/cncr.25983
  • ISSN: 0008-543X; 1097-0142
  • Origination:
  • Footnote:
  • Description: AbstractBACKGROUND:Lenalidomide, an immunomodulatory agent, has activity in lymphoproliferative disorders. The authors, therefore, evaluated its effects on T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia (CLL).METHODS:To study the immunomodulatory effects of lenalidomide in CLL, the authors recruited 24 patients with untreated CLL enrolled in a phase 2 clinical trial of lenalidomide and obtained peripheral blood specimens for immunologic studies consisting of enumeration of T cells and assessing their ability to synthesize cytokines after activation through T‐cell receptor (TCR).RESULTS:After 3 cycles of therapy, patients had a significant reduction in percentage (%) and absolute lymphocyte count (ALC) and an increase in percentage of T cells, percentage of activated CD8+ T cells producing IFN‐γ, and percentage of regulatory T (TR) cells when compared with their respective levels before treatment. After 15 cycles of treatment, responder patients had significant reduction in percentage of lymphocytes and ALC, percentage of activated CD4+ T cells producing IL‐2, IFN‐γ, or TNF‐α, and percentage of TR cells when compared with their perspective levels after 3 cycles of treatment. Furthermore, the numbers of activated CD4+ T cells producing IL‐2, IFN‐γ, or TNF‐α, activated CD8+ T cells producing IFN‐γ, and TR cells normalized to the range of healthy subjects.CONCLUSIONS:Treatment with lenalidomide resulted in the normalization of functional T‐cell subsets in responders, suggesting that lenalidomide may modulate cell‐mediated immunity in patients with CLL. Cancer 2011;. © 2011 American Cancer Society.
  • Access State: Open Access